Drug intelligence / Profile preview

ARX828

Development stage: Preclinical
Lead developer: UMeWorld
Modality: Small Molecules
Administration: Oral

Overview

**ARX828** is an investigational orally administered small-molecule inhibitor of inducible nitric oxide synthase. It was selected by AlphaRx for advanced preclinical development as an anti-inflammatory therapy, with rheumatoid arthritis and inflammatory bowel disease identified as intended indications. By inhibiting inducible nitric oxide synthase, ARX828 was intended to reduce inflammation-associated nitric oxide production. Publicly available information describes animal studies and planned IND-enabling development, but does not establish clinical development, regulatory approval, or commercial manufacture.

Targets

NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on ARX828.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARX828.

Explore the full profile